I have just seen a very important news, for thousands of people, who have already suffered a heart attack. The article states: A new polypill prevents the risk of a second heart attack.
A polypill, adopted by the EU and the Spanish Agency of Medicines, reduces, by two thirds, the likelihood of having a second heart attack. It is called Trinomia, it includes three active ingredients and it has been developed, by researchers, at the National Center for Cardiovascular Research (CNIC).
Trinomia: a polypill that prevents a second heart attack
The drug is for patients, who have undergone a heart attack and require treatment to reduce the chances of a second cardiovascular event, situation that occurs in about 30% of patients, as has assured, at a press conference, the Managing Director of the CNIC, Valentin Fuster.
The polypill, developed by the IASB, in collaboration with the pharmaceutical company Ferrer, has three active ingredients: acetylsalicylic acid, to prevent thrombus formation; artovastatina, to control cholesterol levels and stabilize atherosclerotic plaque; rampiril, an antihypertensive, preventing heart remodeling, that occurs after a heart attack, reported Sync.
For now, Trinomia be marketed, in 15 European countries, and is set to hit another 90, within a period of four years, has indicated Jordi Ramentol, Managing Director of Ferrer, who pointed out that, in Spain, the price of monthly treatment, with this drug, will be around 10 euros.
"It is already implemented in Latin American countries, such as Argentina and Mexico. We anticipate that, in 2016, it will arrive to countries of Asia and will be marketed in Egypt, which has a high incidence of cardiovascular events, at the right price to its economy", added Fuster, who has also emphasized the social nature of this investment.
The main advantages of this drug are improving treatment adherence, ie, people it costs less to take three compounds, in a single capsule, than to take them separately.
To this one, it must be added the cost reduction, "the largest in the marketing of medicines is their distribution, so a single pill could make the pill arrived to places with fewer economic opportunities", said the Managing Director of the CNIC. Another benefit is its accessibility, in developing countries.
To demonstrate adherence to treatment, it was conducted a clinical trial, presented, at the European Society of Cardiology, with patients who had suffered a myocardial infarction, which showed a 22% adherence to the polypill than the components separately. The study was published in the Journal of the American College of Cardiology (JACC).
Another US study, conducted with customers of the largest insurers, in the country, showed that patients, with greater adherence to medication, reduced the risk of cardiovascular events, significantly.
In order to quantify the cost and effectiveness of the pill relationship, the European Commission will finance the SECURE study, which will evaluate the results, in patients from seven European countries, including Spain, starting in October.
The promoters of the drug have asked the World Health Organization (WHO) including Trinomia, in its list of essential drugs, to which the entity will respond next April.
Ramentol estimates the cost of the drug development, at 25 million euros. The Secretary of State for R & D, Carmen Vela, who chaired the presentation of the drug, stressed the need for public-private collaboration, in the Spanish science.
Well, as I said, at the beginning of this post, I think this discovery is so interesting, for Society, because it can help many people. I hope that its effectiveness continues for ever and, even though that pill can be improved.
Until my next post, kind regards,
Luis.
Sponsored by Costaluz Lawyers.
Please click below:
